Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28825960 | 0.90 | TSHR (0.52) | TSHRALDH1A1NPSR1CYP2D6L3MBTL1 | |
| SCHEMBL8084596 | 0.87 | TSHR (0.57) | TSHRALDH1A1NPSR1CYP2D6 | |
| SCHEMBL6655480 | 0.86 | ALDH1A1 (0.43) | TSHRALDH1A1NPSR1CYP2D6L3MBTL1 | |
| SCHEMBL3908306 | 0.86 | SMN1; SMN2 (0.42) | TSHRALDH1A1NPSR1L3MBTL1THRB | |
| SCHEMBL4087213 | 0.85 | ALDH1A1 (0.48) | TSHRALDH1A1NPSR1CYP2D6L3MBTL1 | |
| SCHEMBL18706844 | 0.85 | ALDH1A1 (0.43) | TSHRALDH1A1NPSR1CYP2D6L3MBTL1 | |
| Hydrochloric Acid SCHEMBL27351255 | 0.84 | ALDH1A1 (0.47) | TSHRALDH1A1NPSR1CYP2D6L3MBTL1 | |
| SCHEMBL26828326 | 0.84 | THRB (0.40) | TSHRALDH1A1NPSR1THRBSMN1; SMN2 | |
| SCHEMBL934442 | 0.84 | ALDH1A1 (0.47) | TSHRALDH1A1NPSR1CYP2D6L3MBTL1 | |
| SCHEMBL874451 | 0.83 | ALDH1A1 (0.45) | TSHRALDH1A1NPSR1L3MBTL1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10364256-B2 | Biaryl pyrazoles as NRF2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-30 | — | — | US | disclosed |
| US-10364256-B2 | Biaryl pyrazoles as NRF2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-30 | — | — | US | disclosed |
| US-20180282349-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-10-04 | — | — | US | disclosed |
| WO-2017060854-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-04-13 | — | — | WO | disclosed |
| WO-2017060854-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-04-13 | — | — | WO | disclosed |
| CN-101805241-B | New method for preparing fluoro-substituted indene compound | CHANGZHOU SHENGYONG PHOTOELECTRICITY MATERIALS CO LTD | 2012-11-14 | — | — | CN | disclosed |
| CN-101805241-A | New method for preparing fluoro-substituted indene compound | CHANGZHOU SHENGYONG PHOTOELECTRICITY MATERIALS CO LTD | 2010-08-18 | — | — | CN | disclosed |
| US-7569608-B2 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-08-04 | — | — | US | disclosed |
| US-7569609-B2 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-08-04 | — | — | US | disclosed |
| US-7176240-B2 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-20050267168-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. | 2005-12-01 | — | — | US | disclosed |
| US-20050261371-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. | 2005-11-24 | — | — | US | disclosed |
| CN-1200703-C | Use of pentanoate derivant | ONO PHARMACEUTICAL CO (JP) | 2005-05-11 | — | — | CN | disclosed |
| US-20030096802-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. | 2003-05-22 | — | — | US | disclosed |
| CN-1083419-C | Pentanoic acid derivatives, process for their preparation, pharmaceutical compositions containing them and their use | ONO PHARMACEUTICAL CO (JP) | 2002-04-24 | — | — | CN | disclosed |
| CN-1322524-A | Use of pentanoate derivant | ONO PHARMACEUTICAL CO (JP) | 2001-11-21 | — | — | CN | disclosed |
| US-6201021-B1 | TREATMENT OF DISEASES INDUCED BY REACTIVE ASTROCYTES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-03-13 | — | — | US | disclosed |
| EP-0632008-B1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO (JP) | 1998-02-04 | — | — | EP | disclosed |
| CN-1100408-A | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO (JP) | 1995-03-22 | — | — | CN | disclosed |
| EP-0632008-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267168-A1 | Pentanoic acid derivatives | FFAR3, FFAR1, HCAR3 | TSHR 50/4885ALDH1A1 1709/4885NPSR1 142/4885 |
| US-20030096802-A1 | Pentanoic acid derivatives | FFAR3, FPR1, FPR3 | TSHR 408/4885ALDH1A1 1701/4885NPSR1 212/4885 |
| US-10364256-B2 | Biaryl pyrazoles as NRF2 regulators | NFE2L2, KEAP1, NQO1 | TSHR 3605/4885ALDH1A1 372/4885NPSR1 2851/4885 |
| US-20050261371-A1 | Pentanoic acid derivatives | FFAR3, FFAR1, HCAR3 | TSHR 65/4885ALDH1A1 1869/4885NPSR1 146/4885 |
| US-20180282349-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | NFE2L2, KEAP1, NQO1 | TSHR 3605/4885ALDH1A1 372/4885NPSR1 2851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.